Galcanezumab

Organon Reports Results for the First Quarter Ended March 31, 2024

Retrieved on:

Jeudi, mai 2, 2024

Biotechnology, Vitamins, Supplements, Health, Pharmaceutical, Medical Supplies, Galcanezumab, Bleeding, Etonogestrel, Growth

Women’s Health revenue increased 11% on an as-reported basis, and increased 12% ex-FX in the first quarter of 2024 compared with the first quarter of 2023 primarily driven by 34% ex-FX growth in Nexplanon® (etonogestrel implant).

Key Points:

Women’s Health revenue increased 11% on an as-reported basis, and increased 12% ex-FX in the first quarter of 2024 compared with the first quarter of 2023 primarily driven by 34% ex-FX growth in Nexplanon® (etonogestrel implant).
Biosimilars revenue grew 46% on an as-reported basis and 46% ex-FX in the first quarter of 2024, compared with the first quarter of 2023.
Established Brands revenue was flat on an as-reported basis and grew 2% ex-FX in the first quarter of 2024.
The company expects revenue growth in the Established Brands franchise to be about flat for full year 2024 on an ex-FX basis.

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Retrieved on:

Lundi, décembre 18, 2023

RAYVOW is a first-in-class serotonin 5-HT1F receptor agonist approved for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Key Points:

RAYVOW is a first-in-class serotonin 5-HT1F receptor agonist approved for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
“This commercialization agreement aligns seamlessly with Organon’s suite of central nervous system treatments in our Established Brands portfolio and, most importantly, it further bolsters our offerings to women, who are disproportionately impacted by migraine,” said Kevin Ali, Organon CEO.
“We are confident this collaboration with Organon will help even more people throughout Europe gain access to our innovative migraine treatments.”
Under the terms of the agreement, Organon will become the sole distributor and promoter of Emgality and RAYVOW in Europe.
Total consideration to be paid to Lilly includes an upfront payment of $50 million and sales-based milestone payments.

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on:

Jeudi, octobre 19, 2023

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points:

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
"In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.

At Fifteen Months Post-Launch, AbbVie's Qulipta Outperforms Pfizer's Nurtec ODT on Perceived Overall Efficacy in the Preventive Migraine Space, According to Spherix Global Insights

Retrieved on:

Jeudi, mars 16, 2023

EXTON, Pa., March 16, 2023 /PRNewswire/ -- Spherix Global Insights recently released data from their Launch Dynamix™: Qulipta for Migraine Prevention (US) deep dive study tracking the launch of AbbVie's Qulipta for the preventive treatment of episodic migraines. At fifteen months post-launch, analysis reveals that AbbVie's brand has made significant strides over the course of their entry on prescriber perceptions, including increasingly favorable rating for Qulipta awareness, familiarity, use, satisfaction, likelihood to recommend, and the brand's risk/benefit and cost/benefit ratios.

Key Points:

Use of Qulipta as a preventive migraine treatment still trails Nurtec ODT, but future projections have the brands' use on par.
Furthermore, the past several months have revealed quite a surge for Qulipta preference in a head-to-head comparison with Nurtec ODT among surveyed neurologists and migraine specialists (n=74).
Specifically, Qulipta is viewed as performing better than Nurtec ODT when it comes to overall efficacy and safety, and most notably, favorable dosing schedule.
As one migraine treater noted,
"Qulipta is a good choice and the patient was more comfortable with Qulipta than the Nurtec dosing.

AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China

Retrieved on:

Mardi, janvier 17, 2023

CGRP, Eli Lilly, Therapy, Calcitonin, Quality of life, Eli Lilly and Company, Safety, Migraine, Patient, Prevalence, National Medical Products Administration, Pharmaceutical industry, MHD, Galcanezumab

SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to address critical unmet medical needs in neurological, psychiatric and ophthalmic disorders today announced that it has entered into an agreement with Eli Lilly and Company ("Eli Lilly") to obtain sole commercialization rights to import, market, promote, distribute and detail Galcanezumab once approved in Mainland China. A new drug application for Galcanezumab as a preventative treatment for episodic migraine in adults was submitted by Eli Lilly to China's National Medical Products Administration ("NMPA") in June 2022.

Key Points:

Affamed to obtain sole commercialization rights upon regulatory approval in Mainland China to Galcanezumab, a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP).
Target to address unmet medical needs for millions of Chinese migraine patients.
A new drug application for Galcanezumab as a preventative treatment for episodic migraine in adults was submitted by Eli Lilly to China's National Medical Products Administration ("NMPA") in June 2022.
Significantly greater mean proportions of patients with galcanezumab versus placebo had ≥ 50%, ≥ 75%, and 100% reductions from baseline in MHDs (all p

Migraine Digital Marketing Analysis Report 2022: Biohaven's Nurtec.com Achieved the Highest traffic Across Branded Patient Sites in the US from July 2021 to June 2022

Retrieved on:

Jeudi, décembre 1, 2022

HCP, Digital, AbbVie, HCPS, Allergan, Amgen, Social media, Patient, Eli Lilly and Company, Comparison, Galcanezumab, DDA, SEO, Lundbeck, Pharmaceutical industry, Generic drug, Online shopping, Teva, Migraine

Biohaven's Nurtec.com achieved the highest traffic across branded patient sites in the US from July 2021 to June 2022, with about 14,500,000 visits, followed by Eli Lilly's Emgality.com and Allergan's Botoxchronicmigraine.com.

Key Points:

Biohaven's Nurtec.com achieved the highest traffic across branded patient sites in the US from July 2021 to June 2022, with about 14,500,000 visits, followed by Eli Lilly's Emgality.com and Allergan's Botoxchronicmigraine.com.
The highest proportion of traffic to these sites originated from direct sources, followed by referrals and organic traffic.
For patient branded sites, Lundbeck spent the most on digital display advertising (DDA) for Vyepti.com at $4.6 million, followed by Allergan's Botoxchronicmigraine.com at $4.3 million.
Understand the digital marketing competitive landscape in migraine, with a view of leading patient and HCP branded assets across different regions.

Migraine Digital Marketing Trends Report 2022: Assessment of Pharma Company's Assets in Branded Websites for Patients and Healthcare Professionals (HCPs), Mobile Apps, and Social Media Accounts - ResearchAndMarkets.com

Retrieved on:

Vendredi, novembre 25, 2022

For patient branded sites, Lundbeck spent the most on digital display advertising (DDA) for Vyepti.com at $4.6 million, followed by Allergan's Botoxchronicmigraine.com at $4.3 million.

Key Points:

For patient branded sites, Lundbeck spent the most on digital display advertising (DDA) for Vyepti.com at $4.6 million, followed by Allergan's Botoxchronicmigraine.com at $4.3 million.
This report assesses key digital marketing metrics of pharma assets in migraine, including branded websites for patients and healthcare professionals (HCPs), mobile apps, and social media accounts.
Understand the digital marketing competitive landscape in migraine, with a view of leading patient and HCP branded assets across different regions.
See what pharma social media accounts in migraine are the most active and achieving the most engagement.

Biohaven's Nurtec ODT and AbbVie's Qulipta Emerging as the Top Two Contenders in the Preventive Migraine Space, According to Spherix Global Insights

Retrieved on:

Vendredi, juin 10, 2022

EXTON, Pa., June 10, 2022 /PRNewswire/ -- According to the latest deep dive report included in Spherix's Launch Dynamix™: Qulipta for Migraine Prevention (US) service, surveyed neurologists and migraine specialists report high satisfaction with AbbVie's Qulipta across several performance metrics early in the product's launch. However, Biohaven's Nurtec ODT is reportedly up to par with Qulipta on most attributes, including overall efficacy, safety, tolerability, and favorable dosing schedule.

Key Points:

However, Biohaven's Nurtec ODT is reportedly up to par with Qulipta on most attributes, including overall efficacy, safety, tolerability, and favorable dosing schedule.
In fact, Nurtec ODT outperforms Qulipta on ease of market access and breadth of approved indications.
Respondents anticipate robust six-month projected market share for both products, with a 50% increase for Nurtec ODT and more than 250% for Qulipta.
The EU5 market will be exciting to watch with Biohaven's Vydura (Nurtec ODT in the US) recently gaining approval and Qulipta expected to be approved sometime in 2023.

Robust Uptake of AbbVie's Qulipta Turns Up the Pressure for Amgen, Eli Lilly, and Teva in the Prevention Segment of the Migraine Market, Spherix Reports

Retrieved on:

Mardi, février 8, 2022

The first of six quarterly deep dive reports included in Spherix's Launch Dynamix: Qulipta (AbbVie) for Migraine Prevention (US) service collected the responses of 86 U.S. neurologists and migraine specialists three months post launch.

Key Points:

The first of six quarterly deep dive reports included in Spherix's Launch Dynamix: Qulipta (AbbVie) for Migraine Prevention (US) service collected the responses of 86 U.S. neurologists and migraine specialists three months post launch.
Positive clinical experiences with the oral gepants within the prevention segment foretells competitive headwinds for Aimovig, Eli Lilly's Emgality, and Teva's Ajovy.
Two-thirds of physicians agree that data supporting the efficacy of Qulipta for the prevention of chronic migraine would greatly increase their use of the brand.
Spherix will continue to assess Qulipta perceptions and related prescribing patterns via their ongoing Launch Dynamix, RealTime Dynamix, and RealWorld Dynamix services.

Migraine Disease Analysis Research Report 2021 - ResearchAndMarkets.com

Retrieved on:

Jeudi, janvier 27, 2022

The "Disease Analysis: Migraine" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Disease Analysis: Migraine" report has been added to ResearchAndMarkets.com's offering.
Migraine is a common, disabling, and recurring complex neurological disorder with a genetic component, affecting adults throughout their lifespans.
Both positive symptoms of migraine, such as geometric patterns or flashing lights, and negative symptoms, such as vision impairment, have gradual onset and resolve completely.
The CGRP class in general is well tolerated, works relatively quickly, and has proven to be effective in the prevention of both episodic migraine and chronic migraine.